Rovin Capital Gilead Sciences, Inc. Transaction History

Rovin Capital

$270 Million
Q3 2024

A detailed history of Rovin Capital transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Rovin Capital holds 9,659 shares of GILD stock, worth $871,145. This represents 0.3% of its overall portfolio holdings.

Number of Shares

9,659

Previous 8,433 14.54%

Holding current value

$871,145

Previous $579,000 39.9%

% of portfolio

0.3%

Previous 0.24%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$66.59 - $83.99 $81,639 - $102,971	1,226 Added 14.54%	9,659 $810,000
Q2 2024 Jul 18, 2024	BUY	$63.15 - $72.88 $61,002 - $70,402	966 Added 12.94%	8,433 $579,000
Q1 2024 Apr 22, 2024	SELL	$71.58 - $87.29 $429 - $523	-6 Reduced 0.08%	7,467 $547,000
Q4 2023 Mar 12, 2024	BUY	$73.27 - $83.09 $129,321 - $146,653	1,765 Added 30.92%	7,473 $605,000
Q3 2023 Oct 25, 2023	BUY	$73.94 - $80.67 $192,539 - $210,064	2,604 Added 83.89%	5,708 $428,000
Q2 2023 Aug 08, 2023	SELL	$76.01 - $86.7 $34,660 - $39,535	-456 Reduced 12.81%	3,104 $239,000
Q1 2023 Apr 05, 2023	SELL	$77.31 - $88.08 $316,507 - $360,599	-4,094 Reduced 53.49%	3,560 $295,000
Q4 2022 Jan 23, 2023	SELL	$62.32 - $89.47 $78,336 - $112,463	-1,257 Reduced 14.11%	7,654 $657,000
Q3 2022 Oct 25, 2022	SELL	$59.54 - $68.01 $108,422 - $123,846	-1,821 Reduced 16.97%	8,911 $550,000
Q2 2022 Jul 22, 2022	BUY	$57.72 - $65.01 $31,399 - $35,365	544 Added 5.34%	10,732 $663,000
Q1 2022 Jun 13, 2022	BUY	$57.92 - $72.58 $9,962 - $12,483	172 Added 1.72%	10,188 $606,000
Q4 2021 Feb 24, 2022	BUY	$64.88 - $73.64 $649,838 - $737,578	10,016 New	10,016 $727,000

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rovin Capital , based on Form 13F filings with the SEC.

News

Stay updated on Rovin Capital with notifications on news.

Account